Cargando…
Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma
Aim: To understand the economic burden of relapsed and refractory large B-cell lymphoma patients in Japan treated with salvage chemotherapy. Patients & methods: Patients who received systemic therapy after first-line treatment were analyzed to assess its associated cost and resource use using a...
Autores principales: | Tsutsué, Saaya, Makita, Shinichi, Yi, Jingbo, Crawford, Bruce |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386473/ https://www.ncbi.nlm.nih.gov/pubmed/34414783 http://dx.doi.org/10.2217/fon-2021-0400 |
Ejemplares similares
-
Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A structural equation model (SEM) analysis
por: Tsutsué, Saaya, et al.
Publicado: (2022) -
Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma
por: Tsutsué, Saaya, et al.
Publicado: (2020) -
Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma
por: Goto, Hideki, et al.
Publicado: (2020) -
Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
por: Kato, Koji, et al.
Publicado: (2021) -
Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
por: Munakata, Wataru, et al.
Publicado: (2021)